Neutralization of all endogenous VEGF-A isoforms or VEGF receptor 2 inhibition increased pain sensitivity in chemotherapy-induced neuropathy (Verheyen et al., 2012), but conversely reversed neuropathic (Lin et al., 2010), and acute inflammatory hyperalgesia (Grosios et al., 2004). Here, VEGFA is linked to neuropathy.